Human Pancreas Analysis Program (HPAP) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D), beta cell specific autoimmunity, or rare forms of islet dysfunc...
Source: NIDDK Funding Opportunities - October 10, 2018 Category: Endocrinology Source Type: funding
Human Pancreas Analysis Program for Type-2 Diabetes (HPAP-T2D) (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications to expand the operational scope of the existing Human Pancreas Analysis Program (HPAP) to the study of pancreata recovered from tissue donors with Type 2 Diabetes (T2D) and related metabolic disorders. This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pa...
Source: NIDDK Funding Opportunities - October 10, 2018 Category: Endocrinology Source Type: funding
Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01- Clinical Trial Required)
Funding Opportunity RFA-DK-17-023 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical trials to test a highly reliable, wearable/implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a closed loop system. This research is also intended to study behavioral and physiological aspects of relevance to the use and adoption of these systems. The main goal of this FOA is to improve glucose control and quality of life of patients with type 1 diabetes....
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding
Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 - Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-021 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding
High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-022 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent ...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 15, 2018 Category: Research Source Type: funding
High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent (including acinar, ductal, lymphatic) and neighboring (intestinal, mesenteric and ...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is ...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01- Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical trials to test a highly reliable, wearable/implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a closed loop system. This research is also intended to study behavioral and physiological aspects of relevance to the use and adoption of these systems. The main goal of this FOA is to improve glucose control and quality of life of patients with type 1 diabetes. Only human studies will be considered responsive to this FOA, applications involv...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
High-Resolution Exploration of the Human Islet Tissue Environment [HIRN Human Pancreas Analysis Consortium (HPAC)] (U01 Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) invites cooperative agreement applications that will contribute to a higher resolution understanding of the physical and functional organization of the human islet tissue environment by describing the composition (cellular and molecular) and function of important components of the pancreatic islet and peri-islet tissue architecture, the cell-cell relationships and means of communications used by cell types and cell subtypes within the pancreatic tissue ecosystem, and/or the contribution of adjacent (including acinar, ductal, lymphatic) and neighboring (intestinal, mesenteric and ...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Discovery of Early Type 1 Diabetes Disease Biomarkers in the Human Pancreas [HIRN Consortium on Beta Cell Death and Survival (CBDS)] (U01 - Clinical Trial Not Allowed)
This Funding Opportunity Announcement (FOA) requests applications to explore human pancreatic tissues for the discovery of early biomarkers of T1D pathogenesis, the description of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the development of clinical diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is ...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Clinical, Behavioral and Physiological Research Testing Current and Novel Closed Loop Systems (R01- Clinical Trial Required)
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing clinical trials to test a highly reliable, wearable/implantable, portable, and easy to operate system linking continuous glucose monitoring and pancreatic hormone delivery in a closed loop system. This research is also intended to study behavioral and physiological aspects of relevance to the use and adoption of these systems. The main goal of this FOA is to improve glucose control and quality of life of patients with type 1 diabetes. Only human studies will be considered responsive to this FOA, applications involv...
Source: NIDDK Funding Opportunities - February 15, 2018 Category: Endocrinology Source Type: funding
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Funding Opportunity RFA-DK-17-020 from the NIH Guide for Grants and Contracts. Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomater...
Source: NIH Funding Opportunities (Notices, PA, RFA) - February 14, 2018 Category: Research Source Type: funding
Immune System Engineering For Targeted Tolerance in Type 1 Diabetes (R01 Clinical Trial Not Allowed)
Type 1 diabetes (T1D) results in part from the autoimmune-mediated dysfunction or destruction of insulin-producing pancreatic beta cells. This funding opportunity is for projects that seek to discover ways to change the course of the disease by directly establishing tolerance. Immune responses could be engineered for tolerance induction through the manipulation of antigens, cells, or cellular microenvironments. Collaborations between T1D experts and investigators from other fields, including (but not limited to) cancer immunology and biomaterials engineering, are especially encouraged.Lisa Spain, Ph.D. | RFA-DK-17-020 (Sou...
Source: NIDDK Funding Opportunities - February 14, 2018 Category: Endocrinology Source Type: funding
